Zevra - ADHS - A Star is born (Seite 2)
eröffnet am 06.09.21 11:06:47 von
neuester Beitrag 29.04.24 23:28:00 von
neuester Beitrag 29.04.24 23:28:00 von
Beiträge: 41
ID: 1.352.190
ID: 1.352.190
Aufrufe heute: 2
Gesamt: 4.221
Gesamt: 4.221
Aktive User: 0
ISIN: US4884452065 · WKN: A2QLX7 · Symbol: 1GDA
4,3000
EUR
-0,46 %
-0,0200 EUR
Letzter Kurs 31.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
09.05.24 · globenewswire  |
08.05.24 · globenewswire |
01.05.24 · globenewswire |
29.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2554 | +9.943,20 | |
| 7,9600 | +151,90 | |
| 2,3900 | +32,04 | |
| 6,7800 | +30,13 | |
| 3,1100 | +29,05 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,4800 | -17,80 | |
| 9,6000 | -18,64 | |
| 8,6850 | -20,47 | |
| 2,0400 | -58,87 | |
| 0,8020 | -91,06 |
Beitrag zu dieser Diskussion schreiben
FeedbackHeute ein Neubeginn ? - Acer Th. stimmen in Sonder HV über die Übernahme durch ZEVRA ab
Hallo zusammen,echt tot ist es hier im Forum.
Dabei ist heute einer der wichtigsten Tage für ZEVRA.
Die Aktionäre von Acer Th. stimmen gerade über die Übernahme durch ZEVRA ab. Ich hoffe - sie stimmen zu.
Dann muss aber auch die Vermarktung von Olpruva endlich mal starten und ................
Was meint Ihr ?
Ich hoffe auf Kurse Rtg. Norden.
Pascoe hat das Handtuch geschmissen - er hat das Votum der Aktionäre für Team BLAU verstanden 
Bleibt zu hoffen, dass es gelingt Travis wieder zurückzuholen.
Ich mag mir KemPharm/zevra ohne Travis Mickle gar nicht vorstellen
"At the Company’s recent 2023 Annual Meeting of Stockholders (“Annual Meeting”), Zevra shareholders elected John B. Bode, Douglas W. Calder and Corey Watton to Zevra’s Board. Additionally, as previously announced, Wendy L. Dixon, Ph.D., joined the Zevra Board on the date of the Annual Meeting. After the Annual Meeting, Zevra’s newly configured Board met and unanimously approved the following changes:
The Board accepted the resignation of Richard W. Pascoe from his role as CEO, effective June 1, 2023.
Tamara A. Favorito was unanimously appointed Chair of the Board.
Directors Matthew R. Plooster and Joseph B. Saluri, J.D. have indicated that they will not stand for re-election at the Company’s 2024 Annual Meeting, and that they intend to retire as soon as replacements are found.
The Board intends to appoint an interim-Chief Executive Officer and will immediately initiate a search to identify both a new Chief Executive Officer and replacement Board members.
“On behalf of the Zevra team, we welcome new directors John, Doug, Corey and Wendy to the Board as we strengthen our commitment to working together towards our shared goal of delivering value for all Zevra shareholders,” stated Tamara A. Favorito, Zevra’s Board Chair. “We also thank Dr. Travis Mickle, Richard Pascoe, Christopher Posner and Dr. David Tierney for their many contributions to the Company during their tenures on the Board and as leaders of the Company. I want to especially recognize their efforts and commitment to our shared vision of creating a commercially focused rare disease therapeutics company .”
https://finance.yahoo.com/news/zevra-announces-board-directo…
Bleibt zu hoffen, dass es gelingt Travis wieder zurückzuholen.
Ich mag mir KemPharm/zevra ohne Travis Mickle gar nicht vorstellen
"At the Company’s recent 2023 Annual Meeting of Stockholders (“Annual Meeting”), Zevra shareholders elected John B. Bode, Douglas W. Calder and Corey Watton to Zevra’s Board. Additionally, as previously announced, Wendy L. Dixon, Ph.D., joined the Zevra Board on the date of the Annual Meeting. After the Annual Meeting, Zevra’s newly configured Board met and unanimously approved the following changes:
The Board accepted the resignation of Richard W. Pascoe from his role as CEO, effective June 1, 2023.
Tamara A. Favorito was unanimously appointed Chair of the Board.
Directors Matthew R. Plooster and Joseph B. Saluri, J.D. have indicated that they will not stand for re-election at the Company’s 2024 Annual Meeting, and that they intend to retire as soon as replacements are found.
The Board intends to appoint an interim-Chief Executive Officer and will immediately initiate a search to identify both a new Chief Executive Officer and replacement Board members.
“On behalf of the Zevra team, we welcome new directors John, Doug, Corey and Wendy to the Board as we strengthen our commitment to working together towards our shared goal of delivering value for all Zevra shareholders,” stated Tamara A. Favorito, Zevra’s Board Chair. “We also thank Dr. Travis Mickle, Richard Pascoe, Christopher Posner and Dr. David Tierney for their many contributions to the Company during their tenures on the Board and as leaders of the Company. I want to especially recognize their efforts and commitment to our shared vision of creating a commercially focused rare disease therapeutics company .”
https://finance.yahoo.com/news/zevra-announces-board-directo…
Antwort auf Beitrag Nr.: 73.420.659 von soulist am 07.03.23 09:40:40
Danke
Zevra Therapeutics Fourth Quarter & Full-Year 2022
https://event.on24.com/view/console/unavailable.html?eventid…
ZVRA 4.5100 -15.70%
Zitat von soulist: Eine Bitte an die Moderatoren, der Treadtitel ist nach dem Namenswechsel nicht mehr aktuell. Könnt Ihr bitte die Überschrift
"KemPharm - ADHS - A Star is born"
in
"Zevra - ADHS - A Star is born"
umbenennen?
Vielen Dank!
PPS: Nochmal zu Erklärung des Threadtitels. "A Star is" ist angelehnt an azSTARys, dem ADHS Medikament von Kempharm, jetzt Zevra, was über Corium vertrieben wird.
Danke
Zevra Therapeutics Fourth Quarter & Full-Year 2022
https://event.on24.com/view/console/unavailable.html?eventid…
ZVRA 4.5100 -15.70%
Gemessen an der Beteiligung hier im Thread, werden hoffentlich keine signifikanten Stückzahlen an Zevra (exKempharm) hier in D gehalten.
Ich würde dennoch sehr gern die Investorengruppe um Dan Mangless mit unserem Votum unterstützen.
"...Angesichts der schlechten Aktienkursentwicklung des Unternehmens unter der Aufsicht des derzeitigen Vorstands ist Herr Mangless der festen Überzeugung, dass der Vorstand erneuert werden muss, um sicherzustellen, dass die Interessen der Aktionäre im Vorstandssaal angemessen vertreten werden. Herr Mangless glaubt, dass der Vorstand von den drei hochqualifizierten unabhängigen Direktoren mit relevanten Fähigkeiten und einem gemeinsamen Ziel profitieren wird, Werte zum Nutzen aller Zevra-Aktionäre freizusetzen und zu steigern..."
"...Your vote is important, no matter how few shares of Common Stock you own. Mr. Mangless urges you to sign, date, and return the enclosed BLUE universal proxy card today to vote FOR Mr. John B. Bode, Mr. Douglas W. Calder and Mr. Corey Watton and FOR the Proposal to Repeal the Bylaws..."
https://capedge.com/filing/1434647/0001477932-23-001306/ZVRA…
PS: Eine Bitte an die Moderatoren @CommunitySupport, der Treadtitel ist nach dem Namenswechsel nicht mehr aktuell. Könnt Ihr bitte die Überschrift
"KemPharm - ADHS - A Star is born"
in
"Zevra - ADHS - A Star is born"
umbenennen?
Vielen Dank!
PPS: Nochmal zu Erklärung des Threadtitels. "A Star is" ist angelehnt an azSTARys, dem ADHS Medikament von Kempharm, jetzt Zevra, was über Corium vertrieben wird.
Ich würde dennoch sehr gern die Investorengruppe um Dan Mangless mit unserem Votum unterstützen.
"...Angesichts der schlechten Aktienkursentwicklung des Unternehmens unter der Aufsicht des derzeitigen Vorstands ist Herr Mangless der festen Überzeugung, dass der Vorstand erneuert werden muss, um sicherzustellen, dass die Interessen der Aktionäre im Vorstandssaal angemessen vertreten werden. Herr Mangless glaubt, dass der Vorstand von den drei hochqualifizierten unabhängigen Direktoren mit relevanten Fähigkeiten und einem gemeinsamen Ziel profitieren wird, Werte zum Nutzen aller Zevra-Aktionäre freizusetzen und zu steigern..."
"...Your vote is important, no matter how few shares of Common Stock you own. Mr. Mangless urges you to sign, date, and return the enclosed BLUE universal proxy card today to vote FOR Mr. John B. Bode, Mr. Douglas W. Calder and Mr. Corey Watton and FOR the Proposal to Repeal the Bylaws..."
https://capedge.com/filing/1434647/0001477932-23-001306/ZVRA…
PS: Eine Bitte an die Moderatoren @CommunitySupport, der Treadtitel ist nach dem Namenswechsel nicht mehr aktuell. Könnt Ihr bitte die Überschrift
"KemPharm - ADHS - A Star is born"
in
"Zevra - ADHS - A Star is born"
umbenennen?
Vielen Dank!
PPS: Nochmal zu Erklärung des Threadtitels. "A Star is" ist angelehnt an azSTARys, dem ADHS Medikament von Kempharm, jetzt Zevra, was über Corium vertrieben wird.
Trading Spotlight
February 22, 2023
A MESSAGE FROM RICH PASCOE, OUR CHIEF EXECUTIVE OFFICER
Dear Fellow Shareholders:
We are approaching Rare Disease Day, an important day for the rare disease community and an
important day for us. It's the day each year when the world stands together to show its support
for the 300 million people living with a rare disease and raise awareness for the need to advance
new treatments. There are 7,000 known rare diseases, and a rare disease impacts nearly 1 in 10
people in the United States. Today and every day, we stand with them.
That is why today, February 22, 2023, KemPharm has officially changed its name to Zevra
Therapeutics.
Zevra is Greek for zebra, the internationally recognized symbol of the rare disease community.
The idea came from the medical school adage, "when you hear hoofbeats, don't expect a zebra,"
meaning illness is most likely caused by something common, not rare. However, among the
horses, Zevra is focusing on the zebras, people with rare diseases.
Our new name and brand signify our unwavering commitment to a promise many years in the
making, and in honor of our commitment, we have named our Company for the people, care
partners, and families we serve.
Over the last several years, we have been making iterative and purposeful choices that have
transformed us from a company known for developing prodrugs into an organization intensely
focused on giving promising rare disease therapeutic candidates a fighting chance to reach
patients and improve their quality of life.
In May 2022, we acquired substantially all of the assets of Orphazyme A/S, a Denmark-based
company focused on rare neurological diseases, which included arimoclomol, a product
candidate intended for the treatment of Niemann-Pick disease type C (NPC). We also welcomed
many team members involved in this program, who bring years of valuable and relevant
experience to our Company and connectivity to the NPC patient community.
As we began interacting with the NPC patient community, we recognized that the further we
came on our journey, the further we were from the mission and identity of our former brand. If
we continued to move forward under our old flag, it wouldn't convey how devoted we are to
delivering new treatments to people with rare diseases. We needed to find a way to match our
evolution with the image we wanted to share externally and boldly communicate our vision to
people with rare diseases. We needed to reveal our stripes.
Our evolution was motivated by the responsibility of innovating new medicine for people with
rare diseases of the highest unmet need. Our relationships with patient advocacy groups make
us keenly aware of the severe and debilitating effects of rare diseases, particularly among
children. This propels us, with everything we do, to earn the trust of the rare disease
community as we continue to advance our programs.
We will differentiate ourselves not only through our brand but also through our
accomplishments as we seek to guide numerous therapeutic candidates to FDA approval and
into the hands of patients. We've assembled the pipeline. We've put the people in place. We're
making the investment. The new brand demonstrates that we're serious about our
commitment to rare disease research, drug development, and commercialization.
We look forward to sharing more about our journey and progress in the coming months.
Sincerely,
Richard W. Pascoe
Shareholder and Chief Executive Officer
Zevra Therapeutics, Inc.
https://investors.zevra.com/static-files/3c9364a9-f56f-48db-…
A MESSAGE FROM RICH PASCOE, OUR CHIEF EXECUTIVE OFFICER
Dear Fellow Shareholders:
We are approaching Rare Disease Day, an important day for the rare disease community and an
important day for us. It's the day each year when the world stands together to show its support
for the 300 million people living with a rare disease and raise awareness for the need to advance
new treatments. There are 7,000 known rare diseases, and a rare disease impacts nearly 1 in 10
people in the United States. Today and every day, we stand with them.
That is why today, February 22, 2023, KemPharm has officially changed its name to Zevra
Therapeutics.
Zevra is Greek for zebra, the internationally recognized symbol of the rare disease community.
The idea came from the medical school adage, "when you hear hoofbeats, don't expect a zebra,"
meaning illness is most likely caused by something common, not rare. However, among the
horses, Zevra is focusing on the zebras, people with rare diseases.
Our new name and brand signify our unwavering commitment to a promise many years in the
making, and in honor of our commitment, we have named our Company for the people, care
partners, and families we serve.
Over the last several years, we have been making iterative and purposeful choices that have
transformed us from a company known for developing prodrugs into an organization intensely
focused on giving promising rare disease therapeutic candidates a fighting chance to reach
patients and improve their quality of life.
In May 2022, we acquired substantially all of the assets of Orphazyme A/S, a Denmark-based
company focused on rare neurological diseases, which included arimoclomol, a product
candidate intended for the treatment of Niemann-Pick disease type C (NPC). We also welcomed
many team members involved in this program, who bring years of valuable and relevant
experience to our Company and connectivity to the NPC patient community.
As we began interacting with the NPC patient community, we recognized that the further we
came on our journey, the further we were from the mission and identity of our former brand. If
we continued to move forward under our old flag, it wouldn't convey how devoted we are to
delivering new treatments to people with rare diseases. We needed to find a way to match our
evolution with the image we wanted to share externally and boldly communicate our vision to
people with rare diseases. We needed to reveal our stripes.
Our evolution was motivated by the responsibility of innovating new medicine for people with
rare diseases of the highest unmet need. Our relationships with patient advocacy groups make
us keenly aware of the severe and debilitating effects of rare diseases, particularly among
children. This propels us, with everything we do, to earn the trust of the rare disease
community as we continue to advance our programs.
We will differentiate ourselves not only through our brand but also through our
accomplishments as we seek to guide numerous therapeutic candidates to FDA approval and
into the hands of patients. We've assembled the pipeline. We've put the people in place. We're
making the investment. The new brand demonstrates that we're serious about our
commitment to rare disease research, drug development, and commercialization.
We look forward to sharing more about our journey and progress in the coming months.
Sincerely,
Richard W. Pascoe
Shareholder and Chief Executive Officer
Zevra Therapeutics, Inc.
https://investors.zevra.com/static-files/3c9364a9-f56f-48db-…
Antwort auf Beitrag Nr.: 72.173.610 von soulist am 11.08.22 11:09:47
...und jetzt auch CEO bei KemPharm
“After these many years at KemPharm, I look forward to focusing entirely on the science. With the upcoming arimoclomol NDA resubmission and the advancement of KP1077 into a Phase 2 trial, the opportunity for me to provide my full support to KemPharm’s science team will best allow for the Company to achieve its strategic goal of becoming a rare disease-focused commercial organization,” said Travis C. Mickle, Ph.D., President of KemPharm.
https://finance.yahoo.com/news/kempharm-announces-board-lead…
Zitat von soulist: Pascoe ist ein toller Redner.
...und jetzt auch CEO bei KemPharm
“After these many years at KemPharm, I look forward to focusing entirely on the science. With the upcoming arimoclomol NDA resubmission and the advancement of KP1077 into a Phase 2 trial, the opportunity for me to provide my full support to KemPharm’s science team will best allow for the Company to achieve its strategic goal of becoming a rare disease-focused commercial organization,” said Travis C. Mickle, Ph.D., President of KemPharm.
https://finance.yahoo.com/news/kempharm-announces-board-lead…
Inflation, die Preise steigen - sieht man gut beim Kurs von Kempharm
Chart sieht auch wieder lecker aus - golden cross, starkes Signal...
Chart sieht auch wieder lecker aus - golden cross, starkes Signal...
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Travis hat Wort gehalten und in Q3 die Ergebnisse der CV Studie veröffentlicht
"...this us huge for the future of SDX. Basically. Dose 2X higher has less cardiovascular effects than Ritalin. This can open many doors..."
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
Wed, September 28, 2022 at 1:30 PM
“We are pleased with the initial results from the Phase 1 cardiovascular safety trial of SDX, which demonstrated the potential for ‘higher dose’ formulations of SDX to be safe and well-tolerated. These data add to our confidence that the planned doses for the upcoming Phase 2 trial of KP1077 in IH will provide higher exposures to d-MPH while avoiding the potential for greater cardiovascular safety risk as compared to current methylphenidate products being used off-label,” stated Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm. “Overall, the data suggest that SDX can be safely dosed at levels higher than current products, which is expected to result in improved efficacy. We believe this could position KP1077 as an advancement in the treatment of IH.”
https://finance.yahoo.com/news/kempharm-announces-positive-t…
"...this us huge for the future of SDX. Basically. Dose 2X higher has less cardiovascular effects than Ritalin. This can open many doors..."
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
Wed, September 28, 2022 at 1:30 PM
“We are pleased with the initial results from the Phase 1 cardiovascular safety trial of SDX, which demonstrated the potential for ‘higher dose’ formulations of SDX to be safe and well-tolerated. These data add to our confidence that the planned doses for the upcoming Phase 2 trial of KP1077 in IH will provide higher exposures to d-MPH while avoiding the potential for greater cardiovascular safety risk as compared to current methylphenidate products being used off-label,” stated Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm. “Overall, the data suggest that SDX can be safely dosed at levels higher than current products, which is expected to result in improved efficacy. We believe this could position KP1077 as an advancement in the treatment of IH.”
https://finance.yahoo.com/news/kempharm-announces-positive-t…
doctor01
Bullish
05:21 PM
$KMPH
If you know of any other investment that is as much of a TOTAL NO BRAINER as KemPharm, please let me know and I will put some cash in it as well. Seriously, someone asked for people to post their buys. I have never done that with my position or buys, but I account for 10% of today's volume at this moment.
Why do I continue to buy KemPharm?
IT'S BECAUSE IT IS CURRENTLY LIKE PLAYING POKER AND I CAN SEE EVERYONE'S CARD AND I KNOW THAT I HAVE A WINNING HAND!
Yes, I am likely down more than any other investor at this point in time. However, I have had the wherewithal to ADD AT THESE LEVELS AND CLEARLY SEE WHAT WE HAVE AND WHERE WE ARE GOING. I am NOT hanging around because I am in the red. I am hanging around because I KNOW HOW MUCH GREEN I AM GOING TO HAVE from this investment. It's currently the best game in town!
https://stocktwits.com/doctor01/message/479431387
Bullish
05:21 PM
$KMPH
If you know of any other investment that is as much of a TOTAL NO BRAINER as KemPharm, please let me know and I will put some cash in it as well. Seriously, someone asked for people to post their buys. I have never done that with my position or buys, but I account for 10% of today's volume at this moment.
Why do I continue to buy KemPharm?
IT'S BECAUSE IT IS CURRENTLY LIKE PLAYING POKER AND I CAN SEE EVERYONE'S CARD AND I KNOW THAT I HAVE A WINNING HAND!
Yes, I am likely down more than any other investor at this point in time. However, I have had the wherewithal to ADD AT THESE LEVELS AND CLEARLY SEE WHAT WE HAVE AND WHERE WE ARE GOING. I am NOT hanging around because I am in the red. I am hanging around because I KNOW HOW MUCH GREEN I AM GOING TO HAVE from this investment. It's currently the best game in town!
https://stocktwits.com/doctor01/message/479431387
Durchsuchen
Zevra - ADHS - A Star is born
